GLP-1 drugs expand into oral weight-loss market as study flags possible ED risk

GLP-1 receptor agonists are moving into a new phase in 2026 as oral therapies for chronic weight management enter the market and patient usage continues to climb. At the same time, a recent study in eClinicalMedicine linked the medicines to a modest increase in the risk of erectile dysfunction in men with Type 2 diabetes, while supply issues, higher costs and insurance companies’ reluctance to pay remain part of the category’s rapid expansion.

By 2020, about 4 million people were on GLP-1s, but by 2026, that number has soared to an estimated 30 million. What started in 2005 as a diabetes breakthrough became a cultural phenomenon, and the explosion eventually triggered a supply-chain crisis and evolved into a lightning rod for debates about access, affordability, and ethics.

The most meaningful development shaping the GLP-1 category in 2026 is the arrival of oral therapies for chronic weight management. Injectable semaglutide and tirzepatide proved the class’s clinical power, but they also limited scale because needle aversion, refrigeration requirements and titration schedules kept some patients and physicians at arm’s length. With FDA approval of oral semaglutide for weight management, GLP-1 therapy becomes easier to prescribe, easier to distribute, and easier to imagine as part of routine primary care.

Researchers analyzed electronic health records of over 10,000 men in the United States who had Type 2 diabetes and were newly started on either GLP-1 drugs or DPP-4 inhibitors. Men with a prior history of erectile dysfunction were excluded to better assess new-onset cases. The findings showed that men taking GLP-1 medications had a slightly higher incidence of erectile dysfunction — about 35 cases per 1,000 person-years — compared to 28 cases in those using DPP-4 inhibitors, translating to roughly a 26% increased risk over a three-year period.

When researchers applied stricter statistical adjustments, the association weakened and was no longer clearly significant. The study does not prove that GLP-1 drugs directly cause erectile dysfunction, and more rigorous randomized trials are needed to clarify whether this link is real or simply a reflection of underlying health differences.

The market is also rapidly broadening across formulation, duration, personalization and potential indications. Oral dosing removes frictions for some patients, and Novo’s oral version hit 50,000 weekly subscriptions in its first three weeks on the market. As a result, commercial strategies are evolving in parallel, with lower-priced starter doses, subscription-style cash programs and partnerships with digital health platforms becoming standard.

If the early GLP-1 era was defined by sticker shock, 2026 marks the point where pricing pressure becomes structural. List prices remain high, but the prices actually paid by governments, large purchasers and some consumers are coming down. As patents for the drugs begin to expire, competition is intensifying, while the market remains globally expansive, particularly outside the United States, where there are roughly 300 million obese adults.

Usage of GLP-1 drugs is not new, but their popularity as a weight-loss drug is only recent. That has created another set of problems, from supply issues to higher costs and insurance companies’ reluctance to pay for them. While obesity and diabetes remain the foundation of the category, the conversation has shifted from novelty to acceptance, normalization and the medicines finding new markets.